You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.
The workflow combines Swift's Adaptase technology and RNA library kits with Arbor's myBaits technology for hybridization-based target enrichment of the virus.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.
The partners' "COVID-19 task force" will invest in ePlex molecular testing platforms from GenMark Diagnostics to quadruple UCSF's testing capacity.
The firm shipped research-use-only tests last week to key customers to validate the assay design using clinical samples.
The UK's Biosearch Technologies will distribute Arbor Biosciences' myBaits custom, targeted NGS panels to agricultural and seed breeding companies.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.